Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04039113 · ClinicalTrials.gov registry record · Phase 2
Tezepelumab COPD Exacerbation Study
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 337
- Enrollment target
NCT04039113 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 337 participants.
The verdict
NCT04039113, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 337 participants
- Enrollment target
Study Summary
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Interventions
- OTHER Placebo
- BIOLOGICAL Tezepelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2024-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04039113
The ClinicalTrials.gov registry entry for NCT04039113 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 337 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04039113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04039113 about?
NCT04039113 is a clinical study titled "Tezepelumab COPD Exacerbation Study". A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
What is the current status of trial NCT04039113?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 337 participants. The study started on 2019-07-30. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT04039113?
The interventions under investigation include: Placebo (OTHER), Tezepelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04039113?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.